The stock has a 50 day moving average of $33.70 and a 200-day moving average of $31.73. The Higher end of the revenue forecast is $24.6 Million, while the Lower end of the forecast is $16.4 Million. Pharmaceuticals (NASDAQ:ACAD) last …
Below is a chart showing LE's trailing twelve month trading history, with the $20 strike highlighted in orange: And Acadia Pharmaceuticals Inc (ACAD) options are showing a volume of 8,355 contracts thus far today. That number of contracts …
Neither of the following authors nor any immediate family member has received anything of value from or has stock or …
Dr. Srdjan (Serge) Stankovic, M.D., M.S.P.H., is Executive Vice President, Head - Research and Development of the Company. Dr. Stankovic brings over 20 years of executive level experience in drug development and clinical and …
After the market close yesterday, Acadia Pharmaceuticals Inc (NASDAQ:ACAD) released its second-quarter financial ... which works out to 55 cents per share of its common stock. The consensus estimate was calling for a much wider loss …
Therefore, let’s take a closer look at what smart money thinks about ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). At Q3’s end, a total of 24 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of -8% from …
One company I have favored and owned for its Parkinson's psychosis treatment was Acadia Pharmaceuticals (ACAD). And I currently own Sarepta ... Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the …
Moreover, Acuta Capital Partners Limited Liability Company has 3.22% invested in ACADIA Pharmaceuticals Inc. Pacer Advisors Inc. now owns 13,674 shares of the biopharmaceutical company's stock valued at $470,000 after buying an …
Davis. For a complete fundamental analysis analysis of ACADIA Pharmaceuticals Inc., check out Equities.com’s Stock Valuation Analysis report for ACAD.